10X Competitors

Stocks . Germany . 
Stock . 10X GENOMICS DL
1KJ Stock  EUR 12.61  0.07  0.56%   
10X GENOMICS DL competes with Veeva Systems, Healthequity, Teladoc, and Evolent Health; as well as few others. The company classifies itself under Healthcare sector and is part of Health Information Services industry. Analyzing 10X GENOMICS competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of 10X GENOMICS to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out 10X GENOMICS Correlation with its peers.
For more detail on how to invest in 10X Stock please use our How to Invest in 10X GENOMICS guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of 10X GENOMICS competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
7.2712.6117.95
Details
Intrinsic
Valuation
LowRealHigh
6.7312.0717.41
Details

10X GENOMICS Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between 10X GENOMICS and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of 10X and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of 10X GENOMICS DL does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
COP
+ 1.0
COP
COP
+ 0.98
COPA
COP
+ 0.98
COPA
4LL
+ 0.82
2HE
2HE
+ 0.79
VEE
COPA
+ 0.79
3CM
  
High negative correlations   
9EH
- 0.91
2HE
9EH
- 0.84
VEE
9EH
- 0.77
4LL
COP
- 0.71
1XZ
COP
- 0.7
1XZ
3CM
- 0.7
9EH

Risk-Adjusted Indicators

There is a big difference between 10X Stock performing well and 10X GENOMICS Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze 10X GENOMICS's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
VEE  1.72  0.13  0.06  0.20  1.92 
(1.87)
 3.80 
(2.58)
 15.16 
1KJ  3.72 (0.59) 0.00  0.85  0.00 
 0.00 
 6.10 
(8.15)
 30.50 
2HE  1.56  0.39  0.20  0.55  1.48 
(2.19)
 2.82 
(2.58)
 19.03 
4LL  3.17  0.22  0.06  0.25  3.21 
(3.85)
 8.58 
(5.29)
 19.20 
9EH  3.57 (1.24) 0.00 (0.78) 0.00 
 0.00 
 5.71 
(7.44)
 42.67 
3CM  2.65  0.43  0.11 (0.79) 3.13 
(3.16)
 6.92 
(5.62)
 17.04 
1XZ  4.84 (0.05) 0.00 (0.01) 0.00 
 0.00 
 11.11 
(8.54)
 73.47 
COPA  3.53  0.85  0.18  1.57  3.02 
(6.14)
 11.94 
(7.38)
 44.01 
COP  2.20  0.84  0.34 (25.09) 1.65 
(2.70)
 6.62 
(2.46)
 32.53 
COP  2.40  0.86  0.44  3.55  1.36 
(3.21)
 6.25 
(3.21)
 35.75 
All Fundamental Data

10X GENOMICS Competitive Analysis

The better you understand 10X GENOMICS competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, 10X GENOMICS's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across 10X GENOMICS's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
1KJ VEE 2HE 4LL 9EH 3CM 1XZ COPA COP COP
 0.56 
 12.61 
10X
 2.16 
 207.90 
Veeva
 1.69 
 90.50 
Healthequity
 3.92 
 9.02 
Teladoc
 3.88 
 10.70 
Evolent
 0.54 
 1.85 
RLX
 2.60 
 0.75 
Ping
 0.97 
 20.80 
COMPUGROUP
 0.28 
 21.74 
CompuGroup
 0.64 
 21.58 
Compugroup
Market Volatility
(90 Days Market Risk)
Slightly risky
Very steady
Very steady
Slightly risky
Slightly risky
Dangerous
Out of control
Somewhat reliable
Somewhat reliable
Not too volatile
Market Performance
(90 Days Performance)
Very Weak
Modest
Good
Modest
Very Weak
OK
Very Weak
OK
Good
Good
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Low
Average
Low
Low
Below Average
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Buy
Strong Buy
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Strong Sell
Strong Buy
Current Ratio
6.69
3.73
15.6
3.96
1.96
15.81
3.32
0.91
N/A
0.94
Net Asset
N/A
3.82 B
3.11 B
4.35 B
1.82 B
N/A
17.88 B
N/A
1.79 B
1.79 B
Profit Margin
-0.33
0.19
-0.0707
N/A
-0.0142
0.31
-0.17
0.0639
0.0625
0.0625
EBITDA
(117.15 M)
532.94 M
107.02 M
43.28 M
20.69 M
2.13 B
(1.51 B)
149.63 M
213.92 M
213.99 M
Operating Margin
-0.28
0.23
0.0222
-0.0945
0.0037
0.3
-0.23
0.0821
0.0841
0.0841
Current Valuation
N/A
22.59 B
5.61 B
5.01 B
3.01 B
N/A
2.8 B
N/A
2.74 B
2.74 B
Price To Book
N/A
7.89
2.82
0.75
3.31
N/A
2.24
N/A
2.99
2.99
Five Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.99
Beta
1.67
0.86
0.77
1.03
1.56
0.41
0.8
1.02
1.07
1.07
Number Of Employees
1.24 K
5.48 K
3.69 K
37
4 K
1.24 K
2.8 K
8.83 K
8.83 K
8.83 K
Shares Outstanding
95.6 M
140.92 M
84.64 M
162.84 M
111.05 M
1.55 B
1.12 B
52.23 M
52.23 M
52.23 M
Cash Flow From Operations
(219.4 M)
764.46 M
141 M
189.29 M
(11.55 M)
N/A
(1.4 B)
165.54 M
165.27 M
165.27 M
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.0123
0.0107
0.0107
Total Debt
70.82 M
19.27 M
922.08 M
1.54 B
215.68 M
N/A
189.24 M
685.04 M
18.73 B
587.08 M
Return On Equity
-0.21
0.13
-0.0313
-1.49
-0.0241
0.15
-0.076
0.11
0.12
0.12
Z Score
43.8
N/A
3.0
1.2
10.2
N/A
8.4
1.8
N/A
1.8
Return On Asset
-0.0892
0.0778
0.0037
-0.0129
0.002
0.0782
-0.0524
0.031
0.033
0.033
Book Value Per Share
6.78
21.97
22.25
14.17
8.6
11.76
12.1
12.98
12.87
12.87
Total Asset
N/A
3.82 B
3.11 B
4.35 B
1.82 B
N/A
17.88 B
N/A
1.79 B
1.79 B
Debt To Equity
0.09
1.4
7.5
0.09
24.6
N/A
0.012
1.19
N/A
132.2
Target Price
197.56
344.33
85.5
195.48
28.33
4.23
N/A
N/A
57.0
51.81
Last Dividend Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.5
N/A
N/A
Shares Owned By Institutions
99.56
94.21
98.04
82.07
92.75
29.42
12.43
N/A
29.81
29.81
Market Capitalization
5.23 B
24.26 B
5.19 B
4.13 B
3.69 B
3.17 B
2.81 B
2.72 B
2.38 B
2.34 B
Price To Earning
N/A
86.56
48.79
N/A
N/A
N/A
N/A
53.5
N/A
35.3
Price To Earnings To Growth
N/A
1.28
1.91
N/A
N/A
N/A
N/A
N/A
1.51
N/A
Price To Sales
N/A
12.8
6.2
1.77
2.16
N/A
0.54
N/A
1.73
1.76
Net Income
(504.02 M)
427.39 M
(44.29 M)
(13.66 B)
(19.16 M)
N/A
(1.54 B)
72.32 M
68.97 M
68.97 M
Earnings Per Share
-0.76
2.26
-0.66
-53.1
-0.19
0.21
-0.13
1.37
1.36
1.36
Shares Owned By Insiders
2.6
0.73
1.96
0.96
14.57
39.33
53.5
N/A
50.3
50.3
Revenue
503.71 M
1.85 B
756.56 M
2.41 B
1.35 B
6.9 B
7.33 B
1.13 B
1.03 B
1.03 B
Cash And Equivalents
621.96 M
1.33 B
329.31 M
722.63 M
172.86 M
N/A
9.36 B
91.45 M
N/A
44.29 M
Cash Per Share
5.66
9.03
5.25
4.68
2.11
N/A
8.16
1.73
N/A
0.91
Gross Profit
416.4 M
1.35 B
423.71 M
1.66 B
316.58 M
3.67 B
1.71 B
373.55 M
411.46 M
411.46 M
Day Typical Price
12.61
209.37
90.5
8.81
10.7
1.86
0.75
20.8
21.68
21.6
Accumulation Distribution
N/A
0.0207
N/A
0.0687
N/A
0.0107
N/A
N/A
0.0083
0.0028
Market Facilitation Index
N/A
4.4
N/A
0.62
N/A
0.02
N/A
N/A
0.18
0.06
Daily Balance Of Power
9.2 T
(1.05)
9.2 T
0.5484
9.2 T
(0.50)
(9,223,372,036,855)
9.2 T
0.3333
(2.33)
Period Momentum Indicator
0.07
(4.60)
1.5
0.34
0.4
(0.01)
(0.02)
0.2
0.06
(0.14)
Rate Of Daily Change
1.01
0.98
1.02
1.04
1.04
0.99
0.97
1.01
1.0
0.99
Day Median Price
12.61
210.1
90.5
8.71
10.7
1.86
0.75
20.8
21.65
21.61
Price Action Indicator
0.035
(4.50)
0.75
0.48
0.2
(0.01)
(0.01)
0.1
0.12
(0.10)
Coefficient Of Variation
(904.22)
1505.47
589.98
1727.97
(513.50)
820.58
(289,661)
786.92
539.21
557.74
Mean Deviation
3.72
1.72
1.56
3.17
3.57
2.65
4.84
3.53
2.2
2.4
Jensen Alpha
(0.59)
0.1318
0.3925
0.2158
(1.24)
0.4334
(0.05)
0.8471
0.8362
0.8556
Total Risk Alpha
(0.75)
0.0814
0.3398
0.1175
(1.38)
0.3224
(0.27)
0.6677
0.7078
0.725
Sortino Ratio
N/A
0.0611
0.1952
0.0633
N/A
0.1108
N/A
0.1836
0.3381
0.4413
Downside Variance
N/A
4.24
3.93
11.51
N/A
13.0
N/A
20.79
5.79
3.61
Standard Deviation
5.35
2.38
2.47
4.27
6.14
3.54
9.04
6.84
4.56
4.86
Kurtosis
3.62
3.28
10.96
0.7539
17.57
0.4773
25.74
20.31
31.72
35.31
Potential Upside
6.1
3.8
2.82
8.58
5.71
6.92
11.11
11.94
6.62
6.25
Treynor Ratio
0.8549
0.2031
0.5502
0.2477
(0.78)
(0.79)
(0.01)
1.57
(25.09)
3.55
Maximum Drawdown
30.5
15.16
19.03
19.2
42.67
17.04
73.47
44.01
32.53
35.75
Variance
28.64
5.66
6.11
18.21
37.66
12.54
81.7
46.79
20.78
23.6
Market Risk Adjusted Performance
0.8649
0.2131
0.5602
0.2577
(0.77)
(0.78)
0.0017
1.58
(25.08)
3.56
Risk Adjusted Performance
(0.08)
0.0593
0.1411
0.054
(0.15)
0.1043
0.0089
0.1095
0.1552
0.1504
Skewness
(0.01)
0.917
2.07
0.8589
(2.98)
(0.11)
(3.95)
3.6
4.72
5.22
Semi Deviation
N/A
1.92
1.48
3.21
N/A
3.13
N/A
3.02
1.65
1.36
Information Ratio
(0.12)
0.0529
0.1565
0.0503
(0.20)
0.1128
(0)
0.1224
0.1784
0.1727
Value At Risk
(8.15)
(2.58)
(2.58)
(5.29)
(7.44)
(5.62)
(8.54)
(7.38)
(2.46)
(3.21)
Expected Short fall
N/A
(1.87)
(2.19)
(3.85)
N/A
(3.16)
N/A
(6.14)
(2.70)
(3.21)
Downside Deviation
N/A
2.06
1.98
3.39
N/A
3.61
N/A
4.56
2.41
1.9
Semi Variance
N/A
3.7
2.19
10.33
N/A
9.79
N/A
9.13
2.71
1.86

10X GENOMICS Competition Performance Charts

Five steps to successful analysis of 10X GENOMICS Competition

10X GENOMICS's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by 10X GENOMICS DL in relation to its competition. 10X GENOMICS's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of 10X GENOMICS in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact 10X GENOMICS's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to 10X GENOMICS DL, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your 10X GENOMICS position

In addition to having 10X GENOMICS in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Aluminum Thematic Idea Now

Aluminum
Aluminum Theme
Companies involved in production of aluminum. The Aluminum theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aluminum Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in 10X Stock

10X GENOMICS financial ratios help investors to determine whether 10X Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 10X with respect to the benefits of owning 10X GENOMICS security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY